The biotech industry has been one of the fastest-growing sectors in recent years, with companies working on cutting-edge technologies and treatments to address some of the most pressing medical challenges of our time. As a result, there are many biotech stocks that have seen significant growth in recent years. Below are the top 10 growth stocks in biotech, based on their recent performance and potential for future growth.
1. Moderna (MRNA)
Moderna is a leading biotechnology company that focuses on developing mRNA-based vaccines and therapeutics. The company’s COVID-19 vaccine has been highly successful, and it has several other mRNA-based therapies in its pipeline. Moderna's stock has seen tremendous growth in recent years, with its share price increasing by over 370% in 2021 alone.
2. Regeneron Pharmaceuticals (REGN)
Regeneron Pharmaceuticals is a biotechnology company that develops and produces drugs to treat a wide range of medical conditions. Its portfolio includes treatments for cancer, inflammatory diseases, and eye diseases. The company has seen significant growth in recent years, with its stock price increasing by over 90% in 2021.
3. Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is a biotechnology company that develops therapies for the treatment of cystic fibrosis and other serious diseases. The company's stock has seen tremendous growth in recent years, with its share price increasing by over 60% in 2021.
4. Illumina (ILMN)
Illumina is a biotechnology company that develops and manufactures tools for genetic analysis. Its products are used in research, clinical, and commercial settings to help diagnose and treat a wide range of diseases. Illumina's stock has seen tremendous growth in recent years, with its share price increasing by over 60% in 2021.
5. Amgen (AMGN)
Amgen is a biotechnology company that develops and produces drugs to treat a wide range of medical conditions. Its portfolio includes treatments for cancer, bone diseases, and inflammatory diseases. The company has seen significant growth in recent years, with its stock price increasing by over 40% in 2021.
6. Biogen (BIIB)
Biogen is a biotechnology company that focuses on developing therapies for the treatment of neurological diseases. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company has seen significant growth in recent years, with its stock price increasing by over 35% in 2021.
7. CRISPR Therapeutics (CRSP)
CRISPR Therapeutics is a biotechnology company that focuses on developing gene-based therapies using CRISPR technology. The company has several promising therapies in its pipeline, including treatments for sickle cell disease and beta-thalassemia. The company's stock has seen tremendous growth in recent years, with its share price increasing by over 230% in 2021.
8. Gilead Sciences (GILD)
Gilead Sciences is a biotechnology company that develops and produces drugs to treat a wide range of medical conditions. Its portfolio includes treatments for HIV/AIDS, hepatitis C, and cancer. The company has seen significant growth in recent years, with its stock price increasing by over 25% in 2021.
9. Intuitive Surgical (ISRG)
Intuitive Surgical is a biotechnology company that develops and produces robotic surgical systems. Its products are used in a wide range of surgical procedures, including urologic, gynecologic, and general surgery. The company has seen significant growth in recent years, with its stock price increasing by over 30% in 2021.
10. Novavax (NVAX)
Novavax is a biotechnology company that develops vaccines and therapeutics to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus (RSV), as well as Ebola and other emerging infectious diseases. During 2020, the company redirected its efforts to focus on the development and approval of its NVX-CoV2373 vaccine for COVID-19.
Their vaccine, Nuvaxovid, was approved in the European Union at the end of 2021 and in Canada in February 2022, as the fifth vaccine against COVID-19, following Pfizer/BioNTech, Moderna, Janssen, and AstraZeneca.